Acute liver failure in children
Reading File
Finding Sources
Searching PubMed
"acute liver failure" AND children
Searching the Web
acute liver failure children pediatric etiology management 2024 2025
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
I now have comprehensive content to construct a thorough, well-organized response on acute liver failure in children.
Acute Liver Failure in Children (Pediatric ALF)
Definition
Acute liver failure (ALF) in children is defined as rapid-onset hepatic dysfunction with coagulopathy (INR > 1.5) and, in most definitions, hepatic encephalopathy in a patient without previously recognized liver disease. The onset criterion is typically liver illness for < 6 months; some definitions require no evidence of any prior liver disease whatsoever.
Etiology — Age-Stratified
The cause profile in children differs fundamentally from adults and is strongly influenced by age:
| Age Group | Major Causes |
|---|---|
| Neonates / early infancy | Gestational alloimmune liver disease (GALD / neonatal hemochromatosis), herpes simplex virus (HSV), galactosemia, hereditary fructose intolerance, tyrosinemia type I, mitochondrial hepatopathies, sepsis/ischemia |
| Infants / toddlers | Metabolic disorders (tyrosinemia, Niemann-Pick, Wolman), viral hepatitis (EBV, adenovirus, enterovirus, HSV), drug toxicity (valproic acid) |
| School-age | Autoimmune hepatitis, HAV, HBV, Epstein-Barr/CMV, drug-induced (acetaminophen, valproic acid), Amanita toxin |
| Adolescents | Acetaminophen toxicity (deliberate or accidental), Wilson's disease, autoimmune hepatitis, viral hepatitis |
A critically important feature of pediatric ALF is that 30–50% of cases remain indeterminate even after thorough investigation — the etiology cannot be identified.
Other causes across all pediatric age groups include:
- Drugs: acetaminophen (most common identifiable cause in adolescents), valproic acid, salicylates, isoniazid
- Viruses: hepatitis A, B (rare in children), EBV, CMV, adenovirus, enterovirus, parvovirus B19, HSV (especially in immunosuppressed or neonates)
- Metabolic: Wilson's disease, galactosemia, tyrosinemia type I, hereditary fructose intolerance, fatty acid oxidation defects, urea cycle disorders, mitochondrial disorders (POLG mutations)
- Autoimmune hepatitis — accounts for ~5–10%, can present as ALF
- Vascular: Budd-Chiari syndrome (rare), ischemic hepatitis (cardiac disease, sepsis)
- Reye syndrome (now rare due to aspirin avoidance)
— Bradley and Daroff's Neurology in Clinical Practice; Goldman-Cecil Medicine; Robbins & Kumar Basic Pathology
Pathophysiology
The core pathophysiological event is massive or submassive hepatocyte necrosis, causing:
- Loss of synthetic function → coagulopathy (failure to synthesize clotting factors), hypoalbuminemia, hypoglycemia
- Loss of metabolic function → hyperammonemia, jaundice, lactic acidosis
- Massive cytokine release → tissue hypoxia, systemic inflammatory response, hemodynamic instability
- Cerebral edema — the hallmark of ALF encephalopathy (distinct from chronic liver disease); caused primarily by astrocyte swelling (cytotoxic edema) driven by elevated ammonia → glutamine accumulation in astrocytes
Key distinction: unlike cirrhosis, ALF encephalopathy is driven by cerebral edema (not portosystemic shunting), and lactulose has not been shown to improve ALF survival.
— Goldman-Cecil Medicine; Current Surgical Therapy 14e
Clinical Features
Systemic
- Jaundice (often the initial sign), malaise, anorexia, vomiting
- Coagulopathy: bruising, bleeding, prolonged INR
- Hypoglycemia
- Ascites (particularly in Wilson's disease and subacute ALF)
Hepatic Encephalopathy (HE) — Graded 1–4
Children display age-modified features in early grades:
| Grade | Signs in Children |
|---|---|
| 1 | Mild confusion, irritability, excessive crying, sleep disturbances, short attention span |
| 2 | Excessive sleepiness, inappropriate behavior, intermittent disorientation, unable to perform mental tasks |
| 3 | Profound confusion, stupor, delirium, hyperreflexia, extensor plantar response |
| 4 | Coma ± decerebrate/decorticate posturing (4a: responds to pain; 4b: no response) |
Asterixis (flapping tremor) is characteristic but may be difficult to elicit in young children.
Seizures occur in 10–30% of pediatric patients. Intracranial hypertension and cerebral edema are invariably present in Grade 4 HE and represent the leading cause of death.
— Bradley and Daroff's Neurology in Clinical Practice
Investigations
Immediate workup:
| Category | Tests |
|---|---|
| Synthetic function | PT/INR, factor V level (shortest half-life → most sensitive trend marker), albumin |
| Metabolic | Arterial ammonia, glucose, electrolytes, lactate, bilirubin (total/direct) |
| Liver injury | AST, ALT, GGT, ALP |
| Etiology | HAV IgM, HBsAg/anti-HBc IgM, HCV RNA, HSV IgM/PCR, EBV, CMV; ANA, anti-smooth muscle Ab, anti-LKM (autoimmune); ceruloplasmin, serum copper, 24h urine copper (Wilson's); urine reducing substances (galactosemia); plasma amino acids, urine organic acids, acylcarnitine profile (metabolic); toxicology screen + acetaminophen level |
| Neurological | Head CT (rule out hemorrhage, assess edema); EEG (early alpha-rhythm slowing → delta waves → triphasic waves = poor prognosis); ICP monitoring in Grade 3–4 |
| Renal | Creatinine, urine output (hepatorenal syndrome watch) |
| Hematology | CBC, peripheral smear (hemolysis in Wilson's), blood culture |
Factor V has the shortest half-life of all coagulation factors and is the most sensitive serial biomarker for tracking trends in hepatic synthetic function.
Complications
| Complication | Details |
|---|---|
| Cerebral edema / intracranial hypertension | Occurs in ~80% with Grade 4 HE; most common cause of death; ICP monitoring can guide management |
| Coagulopathy | Factor synthesis failure; high risk of bleeding |
| Hypoglycemia | Impaired gluconeogenesis and glycogenolysis |
| Infections / sepsis | Impaired Kupffer cell function + invasive lines; often bacterial (gram-negative) or fungal |
| Hepatorenal syndrome (HRS) | Acute kidney injury from functional renal vasoconstriction |
| Hemodynamic instability | Vasodilation, low SVR, may require vasopressors |
| Pulmonary dysfunction | ARDS, aspiration, hepatopulmonary syndrome |
| Metabolic acidosis | Lactic acidosis (pH <7.3 is an ominous sign) |
Prognostic Criteria
King's College Criteria (most widely used, PPV 80–100%)
Acetaminophen-induced:
- pH < 7.3, OR
- INR > 6.5 AND serum creatinine > 3.4 mg/dL
Non-acetaminophen:
- INR > 6.5, OR any three of:
- INR > 3.5
- Bilirubin > 17.6 mg/dL
- Age < 10 or > 40 years
- Cause: drug toxicity (non-acetaminophen)
- Time from jaundice onset to encephalopathy > 7 days
Note that "age < 10" is embedded as an adverse prognostic feature in the non-acetaminophen criteria.
Other prognostic indicators:
- Serum alpha-NH-butyric acid may predict spontaneous survival in pediatric ALF
- Factor V level trends
- Grade of encephalopathy at presentation
Management
1. ICU Stabilization — All Cases
All children with ALF should be transferred immediately to a pediatric liver transplant center. Manage in PICU with:
- Continuous glucose monitoring and IV dextrose (prevent hypoglycemia)
- Coagulation support (FFP, vitamin K) only if active bleeding or before procedures
- Avoid unnecessary sedation
- Broad-spectrum antibiotics if signs of infection
- Nutritional support — do not restrict protein excessively (outdated practice)
2. Specific Antidotes / Disease-Directed Therapy
| Etiology | Treatment |
|---|---|
| Acetaminophen | N-acetylcysteine (NAC) IV: 140 mg/kg loading dose, then 70 mg/kg q4h (consider activated charcoal 1 g/kg if within 4h of ingestion) |
| Non-acetaminophen ALF / indeterminate | IV NAC also used (benefit shown in Grade 1–2 HE) |
| HSV hepatitis | IV acyclovir |
| HBV | Nucleoside/nucleotide analogue (entecavir or tenofovir) |
| Autoimmune hepatitis | High-dose corticosteroids (prednisolone); benefit in ALF is controversial — requires specialist judgment |
| Wilson's disease | D-penicillamine/trientine + zinc + plasmapheresis/MARS as bridge to transplant (often needed urgently) |
| Galactosemia | Eliminate galactose/lactose immediately (soy formula) |
| Tyrosinemia type I | Nitisinone (NTBC) |
| Herpes/varicella in neonates | IV acyclovir |
| GALD (neonatal hemochromatosis) | IVIG + exchange transfusion |
| Drug toxicity (other) | Withdraw offending agent; copper chelation for Wilson's |
3. Neurological / ICP Management
- Elevate head of bed 30°
- Minimize stimulation; use sedation/neuromuscular blockade if needed
- ICP monitoring in Grade 3–4 HE; target cerebral perfusion pressure (CPP) > 50 mmHg
- Hyperosmolar therapy: mannitol (0.25–0.5 g/kg IV bolus) or hypertonic saline (3%) to target serum sodium 145–155 mEq/L
- Lactulose/polyethylene glycol for ammonia reduction
- Rifaximin, LOLA (L-ornithine L-aspartate)
- Avoid CT early — insensitive for early cerebral edema; MRI (when stable) may show T1 globus pallidus hyperintensity
- Head CT: rule out hemorrhage; if edema visible on CT, irreversible injury likely and transplant may be contraindicated
4. Extracorporeal Liver Support
Bridging to transplant:
- Therapeutic plasma exchange (TPE) — 2025 meta-analysis (PMID 40035795) supports a survival benefit in pediatric ALF/ACLF
- MARS (Molecular Adsorbent Recirculating System) and PROMETHEUS — used in specialist centers as bridge to transplant
5. Liver Transplantation
The only definitive treatment for irreversible ALF. Indications:
- Meeting King's College Criteria
- Failure to improve or worsening clinical course
- Grade 3–4 HE with cerebral edema
Contraindications include established brain herniation or irreversible neurological injury (cerebral edema visible on CT). 1-year graft survival post-transplant: ~80%; 5-year ~73%.
Pediatric considerations include:
- Living donor liver transplantation (LDLT) — especially valuable for pediatric recipients given size matching
- Split liver grafts
Key Differences: Pediatric vs. Adult ALF
| Feature | Children | Adults |
|---|---|---|
| Most common cause | Indeterminate (30–50%) | Acetaminophen (~50%) |
| Metabolic diseases | Major cause, especially in infants | Rare |
| Autoimmune hepatitis | Significant minority | ~4% |
| Wilson's disease | Important in adolescents | Less common overall |
| Encephalopathy signs | Irritability, crying (Grades 1–2) — easily missed | More classic |
| Prognosis | Indeterminate cases do relatively better | Worse overall |
Recent Evidence
- Autoimmune hepatitis presenting as ALF (PMID 38700362): Individual patient data meta-analysis (2024, Liver Int) — outcomes and management strategies in pediatric AIH presenting as ALF.
- Therapeutic plasma exchange (PMID 40035795): 2025 systematic review/meta-analysis found TPE improves transplant-free survival in pediatric ALF and acute-on-chronic liver failure.
- Dengue-associated ALF (PMID 39024894): Meta-analysis quantifying incidence and mortality in dengue-related ALF (relevant in endemic regions).
Sources: Bradley and Daroff's Neurology in Clinical Practice; Goldman-Cecil Medicine 2-Volume Set; Current Surgical Therapy 14e; Robbins & Kumar Basic Pathology; The Harriet Lane Handbook (23rd ed.); Plum and Posner's Diagnosis and Treatment of Stupor and Coma; PubMed (2024–2025)
This is a shared conversation. Sign in to Orris to start your own chat.